Samuel Xavier Stevens|Samuel Xavier Stevens

Samuel Xavier Stevens|Samuel Xavier Stevens

University of Sydney - Sydney / Australia
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 5148768
person_outline Samuel Xavier Stevens|Samuel Xavier Stevens's MOST POPULAR ARTICLES
1-) Elevated neutrophil‐to‐lymphocyte ratio (NLR) is associated with poorer progression‐free survival in unresectable stage III NSCLC treated with consolidation durvalumabU Nindra, A Shahnam, S Stevens, A Pal, A Nagrial, J Lee, PY Yip, T Adam, ...Thoracic Cancer 13 (21), 3058-3062, 202262022
2-) Influence of EGFR mutation status and PD‐L1 expression in stage III unresectable non‐small cell lung cancer treated with chemoradiation and consolidation …U Nindra, A Shahnam, S Stevens, A Pal, A Nagrial, J Lee, PY Yip, T Adam, ...Asia‐Pacific Journal of Clinical Oncology 20 (1), 16-24, 202452024
3-) 965P Real-world toxicity of consolidation durvalumab following chemoradiotherapy (CRT) in elderly and comorbid patients (pts) with unresectable stage III NSCLC: A multi-centre …S Stevens, U Nindra, A Shahnam, V Bray, A Pal, PY Yip, T Adam, ...Annals of Oncology 33, S989, 202232022
4-) Real world efficacy and toxicity of consolidation durvalumab following chemoradiotherapy in older Australian patients with unresectable stage III non-small cell lung cancerS Stevens, U Nindra, A Shahnam, J Wei, V Bray, A Pal, PY Yip, A Linton, ...Journal of Geriatric Oncology 15 (2), 101705, 202422024
5-) Effect of delayed consolidation durvalumab and timing of treatment on survival outcomes in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated …SX Stevens, U Nindra, A Shahnam, VJ Bray, PY Yip, T Adam, JHJ Lee, ...Journal of Clinical Oncology 40 (16_suppl), e18809-e18809, 202212022